Bicara Therapeutics Inc. (BCAX)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $401k
- Sep 8 · Routine
- Form 4 sales
- 44
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineMay 21 2026
Sold 9,200 shares at $20.42 ($188k)
Hyep Ivan, Chief Financial Officer
10b5-1 planSold 6% of holdings ($3.2M position)145,355 shares left1x usual sizeFiling
- 2 Form 4 saleUnusualJul 8 +48 days
Sold 28,000 shares at $28.84 ($808k)
Hyep Ivan, Chief Financial Officer
10b5-1 planSold 17.7% of holdings ($4.6M position)129,855 shares left3x usual sizeFiling
- 3 Form 4 saleRoutineJul 9 +1 day
Sold 28,750 shares at $28.98 ($833k)
Cohlhepp Ryan, President and COO
10b5-1 planSold 13.7% of holdings ($6.1M position)181,641 shares left2.3x usual sizeFiling
- 4 Form 4 saleRoutineJul 10 +1 day
Sold 10,000 shares at $28.42 ($284k)
Mazumdar Claire, Chief Executive Officer
10b5-1 planSold 2.7% of holdings ($10.6M position)362,152 shares left0.5x usual sizeFiling
- 5 Form 4 saleRoutineAug 10 +31 days
Sold 18,750 shares at $27.98 ($525k)
Cohlhepp Ryan, President and COO
10b5-1 planSold 9.4% of holdings ($5.6M position)181,641 shares left1.5x usual sizeFiling
- 6 Form 4 saleRoutineAug 10 same day
Sold 10,000 shares at $27.98 ($280k)
Mazumdar Claire, Chief Executive Officer
10b5-1 planSold 2.7% of holdings ($10.4M position)362,152 shares left0.7x usual sizeFiling
- 7 Form 4 saleRoutineAug 10 same day
Sold 12,500 shares at $27.97 ($350k)
Hyep Ivan, Chief Financial Officer
10b5-1 planSold 8.8% of holdings ($4M position)129,855 shares left1.4x usual sizeFiling
- 8 Form 4 saleRoutineSep 8 +29 days
Sold 17,500 shares at $22.90 ($401k)
Cohlhepp Ryan, President, COO & Interim CEO
10b5-1 planSold 8.8% of holdings ($4.6M position)181,641 shares left1.4x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (44)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Cohlhepp Ryan | President, COO & Interim CEO | Form 4 sale | 17,500 | $401k | 8.8% | Routine | SEC |
| Aug 10, 2026 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 12,500 | $350k | 8.8% | Routine | SEC |
| Aug 10, 2026 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 10,000 | $280k | 2.7% | Routine | SEC |
| Aug 10, 2026 | Cohlhepp Ryan | President and COO | Form 4 sale | 18,750 | $525k | 9.4% | Routine | SEC |
| Jul 10, 2026 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 10,000 | $284k | 2.7% | Routine | SEC |
| Jul 9, 2026 | Cohlhepp Ryan | President and COO | Form 4 sale | 28,750 | $833k | 13.7% | Routine | SEC |
| Jul 8, 2026 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 28,000 | $808k | 17.7% | Unusual | SEC |
| May 21, 2026 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 9,200 | $188k | 6.0% | Routine | SEC |
| May 18, 2026 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 15,000 | $301k | 4.0% | Routine | SEC |
| May 15, 2026 | Cohlhepp Ryan | President and COO | Form 4 sale | 12,500 | $254k | 6.1% | Routine | SEC |
| Apr 27, 2026 | Raben David | Chief Medical Officer | Form 4 sale | 5,500 | $126k | 9.0% | Routine | SEC |
| Apr 21, 2026 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 9,200 | $212k | 6.0% | Routine | SEC |
| Apr 20, 2026 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 15,000 | $354k | 4.0% | Routine | SEC |
| Apr 15, 2026 | Cohlhepp Ryan | President and COO | Form 4 sale | 12,500 | $288k | 6.0% | Routine | SEC |
| Mar 25, 2026 | Raben David | Chief Medical Officer | Form 4 sale | 5,500 | $104k | 9.0% | Routine | SEC |
| Mar 23, 2026 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 9,200 | $170k | 6.0% | Routine | SEC |
| Mar 20, 2026 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 15,000 | $282k | 4.2% | Routine | SEC |
| Mar 16, 2026 | Cohlhepp Ryan | President and COO | Form 4 sale | 12,500 | $246k | 5.9% | Routine | SEC |
| Mar 9, 2026 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 36,766 | $705k | 9.8% | Routine | SEC |
| Mar 6, 2026 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 8,234 | $154k | 2.4% | Routine | SEC |
| Mar 4, 2026 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 16,518 | $301k | 10.2% | Routine | SEC |
| Mar 4, 2026 | Raben David | Chief Medical Officer | Form 4 sale | 16,500 | $306k | 23.0% | Routine | SEC |
| Mar 3, 2026 | Cohlhepp Ryan | President and COO | Form 4 sale | 17,392 | $316k | 7.8% | Routine | SEC |
| Feb 25, 2026 | Cohlhepp Ryan | President and COO | Form 4 sale | 3,631 | $66k | 1.7% | Routine | SEC |
| Jan 22, 2026 | Cohlhepp Ryan | President and COO | Form 4 sale | 3,828 | $69k | 1.8% | Routine | SEC |
| Jan 22, 2026 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 1,882 | $34k | 1.3% | Routine | SEC |
| Jan 15, 2026 | Cohlhepp Ryan | President and COO | Form 4 sale | 149 | $3k | 0.1% | Routine | SEC |
| Dec 22, 2025 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 9,200 | $168k | 6.0% | Routine | SEC |
| Dec 15, 2025 | Cohlhepp Ryan | President and COO | Form 4 sale | 12,500 | $234k | 6.2% | Routine | SEC |
| Nov 25, 2025 | Raben David | Chief Medical Officer | Form 4 sale | 11,000 | $205k | 23.7% | Routine | SEC |
| Nov 24, 2025 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 41,163 | $776k | 11.7% | Routine | SEC |
| Nov 24, 2025 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 18,400 | $341k | 11.2% | Routine | SEC |
| Nov 21, 2025 | Cohlhepp Ryan | President and COO | Form 4 sale | 12,500 | $226k | 6.1% | Routine | SEC |
| Oct 16, 2025 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 24,103 | $454k | 7.2% | Routine | SEC |
| Oct 15, 2025 | Cohlhepp Ryan | President and COO | Form 4 sale | 12,500 | $227k | 5.9% | Routine | SEC |
| Oct 15, 2025 | Mazumdar Claire | Chief Executive Officer | Form 4 sale | 24,734 | $467k | 7.4% | Routine | SEC |
| Oct 9, 2025 | Raben David | Chief Medical Officer | Form 4 sale | 22,000 | $406k | 38.3% | Routine | SEC |
| Oct 9, 2025 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 6,415 | $117k | 4.2% | Routine | SEC |
| Oct 8, 2025 | Hyep Ivan | Chief Financial Officer | Form 4 sale | 30,385 | $553k | 17.3% | Routine | SEC |
| Oct 7, 2025 | Cohlhepp Ryan | President and COO | Form 4 sale | 50,500 | $912k | 19.9% | Routine | SEC |
| Sep 29, 2025 | Meisner Lara | Chief Legal Officer | Form 4 sale | 33,807 | $499k | 100.0% | Routine | SEC |
| Sep 15, 2025 | Meisner Lara | Chief Legal Officer | Form 4 sale | 15,829 | $182k | 100.0% | Routine | SEC |
| Jun 16, 2025 | Meisner Lara | Chief Legal Officer | Form 4 sale | 15,829 | $165k | 100.0% | Routine | SEC |
| Mar 14, 2025 | Meisner Lara | Chief Legal Officer | Form 4 sale | 79,146 | $1M | 100.0% | Routine | SEC |